EA034213B1 - Способ определения уровня альфа-синуклеина в головном мозге с применением антитела к альфа-синуклеину - Google Patents

Способ определения уровня альфа-синуклеина в головном мозге с применением антитела к альфа-синуклеину Download PDF

Info

Publication number
EA034213B1
EA034213B1 EA201490883A EA201490883A EA034213B1 EA 034213 B1 EA034213 B1 EA 034213B1 EA 201490883 A EA201490883 A EA 201490883A EA 201490883 A EA201490883 A EA 201490883A EA 034213 B1 EA034213 B1 EA 034213B1
Authority
EA
Eurasian Patent Office
Prior art keywords
synuclein
antibody
level
brain
seq
Prior art date
Application number
EA201490883A
Other languages
English (en)
Russian (ru)
Other versions
EA201490883A1 (ru
Inventor
Андреас Вайхофен
Томас Энгбер
Ян Гримм
Original Assignee
Байоджен Интернэшнл Нейросайенз Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Байоджен Интернэшнл Нейросайенз Гмбх filed Critical Байоджен Интернэшнл Нейросайенз Гмбх
Publication of EA201490883A1 publication Critical patent/EA201490883A1/ru
Publication of EA034213B1 publication Critical patent/EA034213B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/38—Pediatrics
    • G01N2800/385—Congenital anomalies
    • G01N2800/387—Down syndrome; Trisomy 18; Trisomy 13

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Neurosurgery (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
EA201490883A 2011-11-02 2012-10-29 Способ определения уровня альфа-синуклеина в головном мозге с применением антитела к альфа-синуклеину EA034213B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161554924P 2011-11-02 2011-11-02
PCT/US2012/062430 WO2013066818A1 (en) 2011-11-02 2012-10-29 USE OF AN ANTI-α-SYNUCLEIN ANTIBODY TO DIAGNOSE AN ELEVATED LEVEL OF α-SYNUCLEIN IN THE BRAIN

Publications (2)

Publication Number Publication Date
EA201490883A1 EA201490883A1 (ru) 2014-10-30
EA034213B1 true EA034213B1 (ru) 2020-01-17

Family

ID=48192661

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201490883A EA034213B1 (ru) 2011-11-02 2012-10-29 Способ определения уровня альфа-синуклеина в головном мозге с применением антитела к альфа-синуклеину

Country Status (13)

Country Link
US (3) US20140295465A1 (enExample)
EP (1) EP2773957B1 (enExample)
JP (1) JP6263473B2 (enExample)
KR (1) KR102036938B1 (enExample)
CN (2) CN107091931A (enExample)
AU (1) AU2012332814B2 (enExample)
BR (1) BR112014010664A2 (enExample)
CA (1) CA2854131C (enExample)
EA (1) EA034213B1 (enExample)
IL (1) IL232373B (enExample)
MX (1) MX356797B (enExample)
WO (1) WO2013066818A1 (enExample)
ZA (1) ZA201403879B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20150831T1 (hr) 2008-12-19 2015-10-09 Biogen International Neuroscience Gmbh Humana anti-alfa- sinuklein auto-protutijela
PL2723379T3 (pl) 2011-06-23 2019-05-31 Biogen Int Neuroscience Gmbh Cząsteczki wiążące przeciwko alfa-synukleinie
JP2017536102A (ja) 2014-10-16 2017-12-07 ジェネンテック, インコーポレイテッド 抗アルファ−シヌクレイン抗体及び使用方法
JP6273338B1 (ja) * 2016-12-05 2018-01-31 磁量生技股▲ふん▼有限公司 パーキンソン病からパーキンソン病認知症を特定する方法
US12049493B2 (en) 2017-01-06 2024-07-30 Abl Bio Inc. Anti-alpha-synuclein antibodies and uses thereof
WO2018128454A1 (ko) * 2017-01-06 2018-07-12 에이비엘바이오 주식회사 항 α-SYN 항체 및 그 용도
JP7136790B2 (ja) 2017-02-17 2022-09-13 ブリストル-マイヤーズ スクイブ カンパニー アルファ-シヌクレインに対する抗体およびその使用
BR112020011875A2 (pt) 2017-12-14 2020-11-24 Abl Bio Inc. anticorpo biespecífico ao a-syn/igf1r e uso do mesmo
GB201803553D0 (en) 2018-03-06 2018-04-18 Univ Newcastle Detection of pathological protein aggregation
WO2020009482A1 (ko) * 2018-07-03 2020-01-09 에이비엘바이오 주식회사 항 알파-시누클레인 항체 및 그 용도
EP3629021A1 (en) * 2018-09-26 2020-04-01 Euroimmun Medizinische Labordiagnostika AG Diagnosis of a neuroautoimmune disease
KR102252879B1 (ko) * 2019-11-15 2021-05-17 성균관대학교산학협력단 혈장 내 aimp2를 이용한 파킨슨 질환의 진단 방법, 이를 위한 조성물 및 이를 포함하는 키트

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080300204A1 (en) * 2005-07-19 2008-12-04 University Of Rochester Alpha-Synuclein Antibodies and Methods Related Thereto
WO2010069603A1 (en) * 2008-12-19 2010-06-24 Neurimmune Therapeutics Ag Human anti-alpha-synuclein autoantibodies
US20110052498A1 (en) * 2008-04-29 2011-03-03 Lars Lannfelt Antibodies and Vaccines for Use in Therapeutic and Diagnostic Methods for Alpha-Synuclein-Related Disorders

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
FR2686087A1 (fr) 1992-01-13 1993-07-16 Inst Nat Sante Rech Med Nouvel antigene lymphocytaire, anticorps correspondant et leurs applications.
AU3117799A (en) * 1998-03-30 1999-10-18 Trustees Of The University Of Pennsylvania, The Method of identifying, diagnosing and treating synuclein positive neurodegenerative disorders
CN1440420A (zh) * 2000-07-07 2003-09-03 万能药制药公司 预防神经组织损伤和治疗α-共核蛋白疾病的方法
GB0203446D0 (en) * 2002-02-14 2002-04-03 Univ Lancaster Detection and/or monitoring of synuclein-related diseases
HUE033325T2 (en) 2007-01-05 2017-11-28 Univ Zuerich Anti-beta-amyloid binder antibodies and their use
CN101308144A (zh) * 2007-05-16 2008-11-19 首都医科大学宣武医院 检测受试者体液内疾病相关蛋白聚合能力的方法
CN101692092B (zh) * 2009-09-24 2013-04-10 首都医科大学宣武医院 定量检测人血清中自体α-突触核蛋白抗体的方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080300204A1 (en) * 2005-07-19 2008-12-04 University Of Rochester Alpha-Synuclein Antibodies and Methods Related Thereto
US20110052498A1 (en) * 2008-04-29 2011-03-03 Lars Lannfelt Antibodies and Vaccines for Use in Therapeutic and Diagnostic Methods for Alpha-Synuclein-Related Disorders
WO2010069603A1 (en) * 2008-12-19 2010-06-24 Neurimmune Therapeutics Ag Human anti-alpha-synuclein autoantibodies

Also Published As

Publication number Publication date
KR102036938B1 (ko) 2019-10-25
ZA201403879B (en) 2018-11-28
CN104040342A (zh) 2014-09-10
KR20140095074A (ko) 2014-07-31
BR112014010664A2 (pt) 2017-04-25
MX2014005378A (es) 2015-01-19
CN107091931A (zh) 2017-08-25
JP6263473B2 (ja) 2018-01-31
EA201490883A1 (ru) 2014-10-30
EP2773957A1 (en) 2014-09-10
US20180011112A1 (en) 2018-01-11
CA2854131A1 (en) 2013-05-10
US20190094245A1 (en) 2019-03-28
WO2013066818A1 (en) 2013-05-10
MX356797B (es) 2018-06-14
CA2854131C (en) 2020-07-07
EP2773957A4 (en) 2015-06-24
AU2012332814B2 (en) 2017-12-14
AU2012332814A1 (en) 2014-06-12
IL232373B (en) 2018-08-30
EP2773957B1 (en) 2017-11-29
HK1201585A1 (en) 2015-09-04
NZ625217A (en) 2016-07-29
JP2014533357A (ja) 2014-12-11
IL232373A0 (en) 2014-06-30
US20140295465A1 (en) 2014-10-02

Similar Documents

Publication Publication Date Title
KR102036938B1 (ko) 뇌에서 상승된 수준의 α-시누클레인을 진단하기 위한 항-α-시누클레인 항체의 용도
JP6875363B2 (ja) 神経変性障害の処置のためのセマフォリン−4d結合分子の使用
US9512224B2 (en) Use of semaphorin-4D binding molecules for treatment of atherosclerosis
BR112019017367A2 (pt) detecção precoce de ativação de célula glial em doenças neurodegenerativas ou neuroinflamatórias
EP3160998A1 (en) Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
HK1201585B (en) Use of an anti-alpha-synuclein antibody to diagnose an elevated level of alpha-synuclein in the brain
NZ625217B2 (en) Use of an anti-?-synuclein antibody to diagnose an elevated level of ?-synuclein in the brain